Cardiac antiplatelet therapy plays a crucial role in managing cardiovascular health by preventing blood clot formation, a common factor in heart-related issues. These therapeutic interventions primarily involve medications that inhibit platelet activity, reducing the risk of blood vessel blockages and potential heart events. Aspirin is a well-known antiplatelet agent widely used in cardiac care, working to hinder platelets from clumping together. Additionally, newer antiplatelet medications, such as clopidogrel and prasugrel, offer alternative options for individuals with specific cardiovascular conditions. The strategic use of antiplatelet therapy is tailored to each patient's unique medical profile, ensuring an effective and personalized approach to maintaining heart health. As ongoing research continues to uncover advancements in cardiovascular medicine, the role of cardiac antiplatelet therapy remains pivotal in the pursuit of comprehensive and targeted cardiovascular care
Title : Surgical fetal stem cells implantation in heart failure patients long term results at 14 years
Federico Benetti, Benetti Foundation, Argentina
Title : Exploring new biomarkers of cardiomyopathy
Shuping Zhong, University of Southern California, United States
Title : The development of human relaxin-2 for heart failure with preserved ejection fraction, HFpEF
Thomas Bernd Dschietzig, Relaxera GmbH & Co. KG, Germany
Title : Cancer and cardiovascular diseases: Common pathogenesis mechanisms and risk factors
Mekhman N Mamedov, National Research Center for Preventive Medicine, Russian Federation
Title : Pulse field ablation for atrial fibrillation complications: What do we know yet
Narendra Kumar, HeartbeatsZ Academy, United Kingdom
Title : Lipoprotein (a): The hidden cardiovascular risk
Syed Raza, Awali Hospital, Bahrain